NCT05054257RecruitingPhase 1
CART19 cells effects in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 20 Jun 2024
- Start date
- 2 Jun 2021
- Lead sponsor
- Institute Of Hematology And Blood Transfusion
- NCT number
- NCT05054257
- EU CT number
- 2024-510815-30-00
- EudraCT number
- 2018-004789-32
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 18
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Hematology and Blood Transfusion Coordinator of this site? Confirm its status | Prague | Czechia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.